Zealand Pharma reports IL-23R antagonists
Zealand Pharma A/S has identified new interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of Crohn’s disease, ulcerative colitis,...
Zealand Pharma A/S has identified new interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of Crohn’s disease, ulcerative colitis, psoriasis and psoriatic arthritis.